[On the treatment of vascular fragility appearing during prolonged anticoagulation].
D000925:Anticoagulants / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D002198:Capillary Fragility / Q000187:drug effects*; D005021:Ethylamines / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006417:Hematuria / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D011693:Purpura / Q000139:chemically induced; D013451:Sulfonic Acids / Q000627:therapeutic use*
D000925:Anticoagulants; D005021:Ethylamines; D006490:Hemostatics; D013451:Sulfonic Acids
Traitement de la fragilité vasculaire apparaissant au cours de l'anticoagulation prolongée.